FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1985443857> ?p ?o ?g. }

• W1985443857 endingPage "75" @default.
• W1985443857 startingPage "71" @default.
• W1985443857 abstract "The action of secretory phospholipase A2 (sPLA2) on lipoproteins may render them more susceptible to oxidation, thereby promoting vascular inflammation and increasing cardiovascular risk. Patients with acute coronary syndrome face a high risk of early, recurrent cardiovascular events that is associated with biomarkers of inflammation, including sPLA2. The Vascular Inflammation Suppression to Treat Acute Coronary Syndrome for 16 Weeks (VISTA-16, NCT01130246) tests the hypothesis that varespladib methyl, an inhibitor of several sPLA2 isoforms with a causal role in atherosclerosis, reduces cardiovascular risk among patients with acute coronary syndromes. Up to 6,500 patients with acute coronary syndrome will be randomized to receive treatment with varespladib methyl 500 mg daily or placebo for 16 weeks, in addition to background treatment with atorvastatin and other evidence-based therapies. The primary efficacy parameter is the combination of cardiovascular death, nonfatal myocardial infarction, nonfatal stroke or hospitalization for unstable angina with objective evidence of myocardial ischemia. Effects of varespladib methyl on lipid and inflammatory markers, in addition to safety and tolerability, will also be evaluated. sPLA2 inhibition has the potential to exert a favorable effect on the artery wall. The VISTA-16 study will determine whether varespladib methyl has a beneficial impact on cardiovascular events in patients with an acute coronary syndrome." @default.
• W1985443857 created "2016-06-24" @default.
• W1985443857 creator A5006919099 @default.
• W1985443857 creator A5008067993 @default.
• W1985443857 creator A5049961176 @default.
• W1985443857 creator A5055849986 @default.
• W1985443857 creator A5060465607 @default.
• W1985443857 creator A5065063579 @default.
• W1985443857 creator A5077848934 @default.
• W1985443857 creator A5083542202 @default.
• W1985443857 date "2011-11-24" @default.
• W1985443857 modified "2023-09-23" @default.
• W1985443857 title "Inhibition of Secretory Phospholipase A2 in Patients with Acute Coronary Syndromes: Rationale and Design of the Vascular Inflammation Suppression to Treat Acute Coronary Syndrome for 16 Weeks (VISTA-16) Trial" @default.
• W1985443857 cites W1696959307 @default.
• W1985443857 cites W1966556984 @default.
• W1985443857 cites W1979577320 @default.
• W1985443857 cites W1986097045 @default.
• W1985443857 cites W1994186204 @default.
• W1985443857 cites W2008795060 @default.
• W1985443857 cites W2027212497 @default.
• W1985443857 cites W2031848840 @default.
• W1985443857 cites W2038285115 @default.
• W1985443857 cites W2063612356 @default.
• W1985443857 cites W2073190601 @default.
• W1985443857 cites W2081953245 @default.
• W1985443857 cites W2105744041 @default.
• W1985443857 cites W2110551379 @default.
• W1985443857 cites W2114408062 @default.
• W1985443857 cites W2122602300 @default.
• W1985443857 cites W2128901862 @default.
• W1985443857 cites W2131110587 @default.
• W1985443857 cites W2132901141 @default.
• W1985443857 cites W2134339246 @default.
• W1985443857 cites W2136751995 @default.
• W1985443857 cites W2146461935 @default.
• W1985443857 cites W2166854945 @default.
• W1985443857 cites W2167630046 @default.
• W1985443857 doi "https://doi.org/10.1007/s10557-011-6358-9" @default.
• W1985443857 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22109255" @default.
• W1985443857 hasPublicationYear "2011" @default.
• W1985443857 type Work @default.
• W1985443857 sameAs 1985443857 @default.
• W1985443857 citedByCount "41" @default.
• W1985443857 countsByYear W19854438572012 @default.
• W1985443857 countsByYear W19854438572013 @default.
• W1985443857 countsByYear W19854438572014 @default.
• W1985443857 countsByYear W19854438572015 @default.
• W1985443857 countsByYear W19854438572016 @default.
• W1985443857 countsByYear W19854438572017 @default.
• W1985443857 countsByYear W19854438572018 @default.
• W1985443857 countsByYear W19854438572019 @default.
• W1985443857 countsByYear W19854438572020 @default.
• W1985443857 countsByYear W19854438572022 @default.
• W1985443857 countsByYear W19854438572023 @default.
• W1985443857 crossrefType "journal-article" @default.
• W1985443857 hasAuthorship W1985443857A5006919099 @default.
• W1985443857 hasAuthorship W1985443857A5008067993 @default.
• W1985443857 hasAuthorship W1985443857A5049961176 @default.
• W1985443857 hasAuthorship W1985443857A5055849986 @default.
• W1985443857 hasAuthorship W1985443857A5060465607 @default.
• W1985443857 hasAuthorship W1985443857A5065063579 @default.
• W1985443857 hasAuthorship W1985443857A5077848934 @default.
• W1985443857 hasAuthorship W1985443857A5083542202 @default.
• W1985443857 hasBestOaLocation W19854438571 @default.
• W1985443857 hasConcept C126322002 @default.
• W1985443857 hasConcept C127413603 @default.
• W1985443857 hasConcept C164705383 @default.
• W1985443857 hasConcept C168563851 @default.
• W1985443857 hasConcept C197934379 @default.
• W1985443857 hasConcept C2776914184 @default.
• W1985443857 hasConcept C2777482532 @default.
• W1985443857 hasConcept C2777628954 @default.
• W1985443857 hasConcept C2777698277 @default.
• W1985443857 hasConcept C2777785093 @default.
• W1985443857 hasConcept C2778213512 @default.
• W1985443857 hasConcept C2778375690 @default.
• W1985443857 hasConcept C2780645631 @default.
• W1985443857 hasConcept C500558357 @default.
• W1985443857 hasConcept C71924100 @default.
• W1985443857 hasConcept C78519656 @default.
• W1985443857 hasConceptScore W1985443857C126322002 @default.
• W1985443857 hasConceptScore W1985443857C127413603 @default.
• W1985443857 hasConceptScore W1985443857C164705383 @default.
• W1985443857 hasConceptScore W1985443857C168563851 @default.
• W1985443857 hasConceptScore W1985443857C197934379 @default.
• W1985443857 hasConceptScore W1985443857C2776914184 @default.
• W1985443857 hasConceptScore W1985443857C2777482532 @default.
• W1985443857 hasConceptScore W1985443857C2777628954 @default.
• W1985443857 hasConceptScore W1985443857C2777698277 @default.
• W1985443857 hasConceptScore W1985443857C2777785093 @default.
• W1985443857 hasConceptScore W1985443857C2778213512 @default.
• W1985443857 hasConceptScore W1985443857C2778375690 @default.
• W1985443857 hasConceptScore W1985443857C2780645631 @default.
• W1985443857 hasConceptScore W1985443857C500558357 @default.
• W1985443857 hasConceptScore W1985443857C71924100 @default.
• W1985443857 hasConceptScore W1985443857C78519656 @default.
• W1985443857 hasIssue "1" @default.
• W1985443857 hasLocation W19854438571 @default.

• next